secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000950170-23-000179
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia sets 2023 milestones: NTLA-2001 IND mid-year, $1.3B cash
-----------------------------------------------------------------

- Cash, cash equivalents and marketable securities ~$1.3B as of Dec 31, 2022.
- NTLA-2001 IND submission mid-2023 for global pivotal trial in ATTR-CM; study start by year-end.
- NTLA-2002 (HAE) Phase 2 study initiation and IND submission in 1H 2023.
- NTLA-3001 (gene insertion for AATD) IND or equivalent filing in 2H 2023.
- Additional clinical data from NTLA-2001 and NTLA-2002 studies expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023000179/0000950170-23-000179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023000179/ntla-20230105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer